跳至主要内容
临床试验/IRCT20200731048257N1
IRCT20200731048257N1招募中3 期

Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19 a Multi-center Randomized Blinding Clinical Trial Study

Bagheiat-allah University of Medical Sciences0 个研究点目标入组 224 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
224

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 75 years(—)
性别
All

入选标准

  • informed consent to participate in the study
  • Patients 18 to 75 years of age with COVID-19 who have been diagnosed with PCR
  • Strong clinical suspicion of covid 19 with positive findings in CT Scan
  • Shortness of breath

排除标准

  • Patients with HIV
  • Patients with cancer undergoing chemotherapy
  • Patients receiving Immune Mediators
  • Patients need hospitalization in the intensive care unit
  • Patients with uncontrolled heart, kidney or liver failure
  • Pregnant or lactating women
  • Intolerance to the drugs used in this study (symptoms such as diarrhea, nausea, vomiting and respiratory problems)

研究者

发起方
Bagheiat-allah University of Medical Sciences

相似试验